Key result
Atrial fibrillation was associated with significantly higher serum NT-proBNP levels (689.56 +/- 251.87 fmol/ml) compared to sinus rhythm (456.11 +/- 148.14 fmol/ml, P<0.01).
Why the study?
Are serum NT-proBNP levels elevated in patients with atrial fibrillation compared to those with sinus rhythm or healthy controls?
Observational (n=166)
Are serum NT-proBNP levels elevated in patients with atrial fibrillation compared to those with sinus rhythm or healthy controls?
Absolute Event Rate: 689.56% vs 456.11%
p-value: p=<0.01
Serum NT-proBNP levels are significantly elevated in patients with atrial fibrillation independent of heart failure, and are independently predicted by older age and larger right atrial diameter.
May confound NT-proBNP interpretation for HF in AF; leaves open independent prognostic value.
BACKGROUND: Brain natriuretic peptide (BNP) is increasingly being used for screening and monitoring of congestive heart failure. However, the role of BNP in patients with atrial fibrillation (AF) and normal left ventricular function has not been determined. This study investigates serum N-terminal pro-brain natriuretic peptide (NT-proBNP) level and its clinical implications in patients with AF. METHODS: Serum NT-proBNP levels were measured by enzyme-linked immunosorbent assay (ELISA) and transthoracic echocardiography was performed in 136 subjects (90 cases with AF and 46 cases with sinus rhythm [SR]). Subjects were excluded if they had a history of myocardial infarction, cardiomyopathy, rheumatic heart disease, or hyperthyroidism that preceded the onset of AF. Controls (n = 30) were from a healthy outpatient primary care population. Potential determinants of serum NT-proBNP levels were identified by univariate and multivariate analyses. RESULTS: Individuals with AF had higher serum NT-proBNP levels (689.56 +/- 251.87 fmol/ml) than those with SR (456.11 +/- 148.14 fmol/ml, P < 0.01) and control subjects (415.83 +/- 62.02 fmol/ml, P < 0.01). Individuals with SR and control subjects did not show significant difference at serum NT-proBNP levels (P > 0.05). The regression model of serum NT-proBNP levels and clinical predictors showed that presence of AF, older age, and larger right atrial diameter were independently predictive of higher serum NT-proBNP values. CONCLUSIONS: Patients with AF were associated with increased serum NT-proBNP levels. Examining the change of serum NT-proBNP levels is helpful to evaluate the cardiac function in patients with AF.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2009) conducted an observational in Atrial fibrillation (n=166). Atrial fibrillation vs. Sinus rhythm and healthy controls was evaluated on Serum NT-proBNP levels (fmol/ml) (p=<0.01). Atrial fibrillation was associated with significantly higher serum NT-proBNP levels (689.56 +/- 251.87 fmol/ml) compared to sinus rhythm (456.11 +/- 148.14 fmol/ml, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: